Last updated: September 25, 2020
Pharmacosmos Therapeutics Inc.
A Note About Children. This Site is directed toward adults and we do not knowingly gather Personal Data from visitors who are under the age of 13. If we discover that a child under 18 has submitted Personal Data to Pharmacosmos, we will attempt to delete the information as soon as possible. If you believe that we might have any Personal Data from a child under 13, please contact us at email@example.com.
A Note to Users Outside of the United States. Your Personal Data may be processed in the country in which it was collected and in other countries, including the United States, where laws regarding the processing of Personal Data may be less protective than the laws in your country. By providing your data, you consent to such processing and transfer.
Types of Data We Collect. “Personal Data” means data that, by itself, allows someone to identify or contact you as an individual, including, for example, your name, address, telephone number, e-mail address, as well as any other non-public information about you that is associated with or linked to any of the foregoing data. “Anonymous Data” means data that does not, by itself, permit the identification of individual persons and that is not associated with or linked to Personal Data. We collect Personal Data and Anonymous Data, as described below.
(a) Information You Provide to Us.
(b) Information Collected via Technology.
Use of Your Personal Data
(a) General Use. In general, Personal Data you submit to us is used either to respond to requests that you make, aid us in serving you better, and improve our Site. We and our authorized service providers may use your Personal Data in various ways, including to:
(b) Creation of Anonymous Data. We may create Anonymous Data records from Personal Data by excluding information (such as your name) that makes the data personally identifiable to you. We reserve the right to use Anonymous Data for any purpose and disclose Anonymous Data to third parties in our sole discretion.
(c) Third-Party Data. From time to time, we may use or augment your Personal Data with information obtained from a third party source. For example, we may use Personal Data in conjunction with information obtained from a state licensing board to verify the licensure of healthcare professionals.
(a) Third-Party Service Providers. We may share your Personal Data with third-party service providers that conduct quality assurance testing, provide technical or customer support, and/or provide other services to Pharmacosmos, including to assist us in analyzing how our Site is used. We have contracts in place with such organizations that prevent them from using Personal Data in any other way than how we instruct them. These contracts also require them to maintain good standards of security to ensure the confidentiality of your Personal Data.
Your Choices Regarding Information. You have several choices regarding the use of information on our Service:
(a) Cookies. If you decide at any time that you no longer wish to accept Cookies for any of the purposes described above, then you can instruct your browser, by changing its settings, to stop accepting Cookies or to prompt you before accepting a Cookie from the websites you visit. Consult your browser’s technical information. If you do not accept Cookies, however, you may not be able to use all portions of the Site or all functionality of the Site. If you have any questions about how to disable or modify Cookies, please let us know at the contact information provided above.
(b) Accessing, Changing or Deleting Your Personal Data. You may request deletion of your Personal Data by us, and we will use commercially reasonable efforts to honor your request, but please note that we may be required to keep such information and not delete it (or to keep this information for a certain time, in which case we will comply with your deletion request only after we have fulfilled such requirements). When we delete any information, it will be deleted from the active database, but may remain in our archives. We may also retain your information for fraud prevention or similar purposes.
Security and Risk of Disclosure. We use a variety of security measures and technologies to help protect your Personal Data from unauthorized access, use, disclosure, alteration, or destruction in line with applicable data protection and privacy laws. However, no Internet transmission is ever 100% secure or error-free. More specifically, information transmitted to or from the Site may not be via a secure connection. As a result, you should take particular care in deciding what information you send via our Site.
Retention. We will retain your Personal Data as long as necessary to provide you the services offered there through and the other permitted uses specified herein, and for a reasonable transition time thereafter. We may store Anonymous Data (i.e., information that is not Personal Data) indefinitely.
Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:
- who have intolerance to oral iron or have had unsatisfactory response to oral iron
- who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
IMPORTANT SAFETY INFORMATION
Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.
Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.
Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.